Department of Orthopaedic Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Department of Orthopaedic Surgery, Daejeon Eulji Medical Center, Eulji University School of Medicine, Daejeon, Republic of Korea.
J Bone Joint Surg Am. 2021 Aug 4;103(15):1402-1410. doi: 10.2106/JBJS.20.01663.
The effects of nonsteroidal anti-inflammatory drugs (NSAIDs)/cyclooxygenase (COX)-2 inhibitors on postoperative fracture-healing are controversial. Thus, we investigated the association between NSAID/COX-2 inhibitor administration and postoperative nonunion or delayed union of fractures. We aimed to determine the effects of NSAID/COX-2 inhibitor administration on postoperative fracture-healing with use of a common data model.
Patients who underwent operative treatment of a fracture between 1998 and 2018 were included. To determine the effects of NSAID/COX-2 inhibitor administration on fracture-healing, postoperative NSAID/COX-2 inhibitor users were compared and 1:1 matched to nonusers, with 3,264 patients matched. The effect of each agent on bone-healing was determined on the basis of the primary outcome (nonunion/delayed union), defined as having a diagnosis code for nonunion or delayed union ≥6 months after surgery. The secondary outcome was reoperation for nonunion/delayed union. To examine the effect of NSAIDs/COX-2 inhibitors on bone union according to medication duration, a Kaplan-Meier survival analysis was performed.
Of the 8,693 patients who were included in the analysis, 208 had nonunion (178 patients; 2.05%) or delayed union (30 patients; 0.35%). Sixty-four (30.8%) of those 208 patients had a reoperation for nonunion or delayed union. NSAID users showed a significantly lower hazard of nonunion compared with the matched cohort of nonusers (hazard ratio, 0.69 [95% confidence interval, 0.48 to 0.98]; p = 0.040) but did not show a significant difference in the other matched comparison for any other outcomes. Kaplan-Meier survival analysis revealed significantly lower and higher nonunion/delayed union rates when the medication durations were ≤3 and >3 weeks, respectively (p = 0.001). For COX-2 inhibitors, the survival curve according to the medication duration showed no significant difference among the groups (p = 0.9).
Our study demonstrated no short-term impact of NSAIDs/COX-2 inhibitors on long-bone fracture-healing. However, continued use of these medications for a period of >3 weeks may be associated with higher rates of nonunion or delayed union.
Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.
非甾体抗炎药(NSAIDs)/环氧化酶(COX)-2 抑制剂对术后骨折愈合的影响存在争议。因此,我们研究了 NSAID/COX-2 抑制剂的使用与骨折术后非愈合或延迟愈合之间的关系。我们旨在使用通用数据模型确定 NSAID/COX-2 抑制剂的使用对术后骨折愈合的影响。
纳入 1998 年至 2018 年间接受手术治疗的骨折患者。为了确定 NSAID/COX-2 抑制剂的使用对骨折愈合的影响,将术后 NSAID/COX-2 抑制剂使用者与非使用者进行比较,并进行 1:1 匹配,共匹配了 3264 名患者。根据主要结局(非愈合/延迟愈合)确定 NSAID 每种药物对骨愈合的影响,定义为术后≥6 个月有非愈合或延迟愈合的诊断代码。次要结局是针对非愈合/延迟愈合进行再次手术。为了根据药物使用时间检查 NSAIDs/COX-2 抑制剂对骨愈合的影响,进行了 Kaplan-Meier 生存分析。
在纳入分析的 8693 名患者中,有 208 名发生非愈合(178 名患者;2.05%)或延迟愈合(30 名患者;0.35%)。208 名患者中有 64 名(30.8%)因非愈合或延迟愈合而进行了再次手术。与未使用者相比,NSAID 使用者的非愈合风险显著降低(风险比,0.69 [95%置信区间,0.48 至 0.98];p = 0.040),但在其他任何结局的其他匹配比较中均无显著差异。Kaplan-Meier 生存分析显示,当用药时间≤3 周和>3 周时,非愈合/延迟愈合的发生率分别显著降低和升高(p = 0.001)。对于 COX-2 抑制剂,根据用药时间的生存曲线显示,各组之间无显著差异(p = 0.9)。
我们的研究表明,NSAIDs/COX-2 抑制剂在短期内对长骨骨折愈合没有影响。然而,这些药物的持续使用超过 3 周可能与更高的非愈合或延迟愈合率相关。
治疗性 III 级。有关证据水平的完整描述,请参见作者说明。